MARKET PRICE AND DIVIDEND INFORMATION. Panacea Panacea’s units, Class A common stock and public warrants are currently listed on the NYSE under the symbols “PANA.U”, “PANA” and “PANA WS”, respectively. The closing price of the Panacea Class A common stock, units and public warrants on October 20, 2020, the last trading day before the public announcement of the Business Combination, was $11.10, $11.54 and $1.90, respectively. As of December 29, 2020, the Panacea record date, the closing price for each unit, Class A common stock and public warrant was $11.33, $10.53 and $2.51, respectively. Holders of the units, Class A common stock and public warrants should obtain current market quotations for their securities. The market price of Panacea’s securities could vary at any time before the merger. Holders As of December 29, 2020, there were three holders of record of Panacea’s units, one holder of record of Panacea Class A common stock, six holders of record of founder shares and one holder of record of Panacea’s public warrants. The number of holders of record does not include a substantially greater number of “street name” holders or beneficial holders whose units, public shares and public warrants are held of record by banks, brokers and other financial institutions. Dividend Policy Panacea has not paid any cash dividends on its common stock to date and does not intend to pay cash dividends prior to the completion of the merger. The payment of cash dividends in the future will be dependent upon New Nuvation Bio’s revenues and earnings, if any, capital requirements and general financial condition subsequent to completion of the merger. The payment of any cash dividends subsequent to the merger will be within the discretion of New Nuvation Bio’s board of directors at such time. Nuvation Bio Historical market price information for Nuvation Bio’s capital stock is not provided because there is no public market for Nuvation Bio’s capital stock. See “Nuvation Bio Management’s Discussion and Analysis of Financial Condition and Results of Operations” beginning on page 205 of this proxy statement/prospectus.
MARKET PRICE AND DIVIDEND INFORMATION. Allarity A/S Allarity A/S’s ordinary shares are currently listed on the First North Market in Stockholm under the symbol “XXXX.XX”. The closing price of Allarity A/S ordinary shares on May 20, 2021, the last trading day before the public announcement of the Recapitalization Share Exchange, was SEK 0.83. As of November 5, 2021, the date of this information statement/prospectus, the most recent closing price for Allarity A/S ordinary shares was SEK 1.49. Holders of Allarity A/S ordinary share should obtain current market quotations for their shares. The market price of Allarity A/S’s ordinary shares could vary at any time before the Recapitalization. Holders As of the date of this information statement/prospectus, there were approximately 139 holders of record of Xxxxxxxx A/S’s ordinary shares. The number of holders of record does not include a substantially greater number of “street name” holders or beneficial holders whose ordinary shares are held of record by banks, brokers and other financial institutions.
MARKET PRICE AND DIVIDEND INFORMATION. 24 Dividends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
MARKET PRICE AND DIVIDEND INFORMATION. The closing price of Cleveland BioLabs common stock on October 16, 2020, the last trading day prior to the public announcement of the merger, was $2.17 per share and the closing price of Cleveland BioLabs common stock on June 9, 2021 was $5.45 per share, in each case as reported on Nasdaq. Because the market price of Cleveland BioLabs common stock is subject to fluctuation, the market value of the shares of Cleveland BioLabs common stock that Cytocom stockholders will be entitled to receive in the merger may increase or decrease. Cytocom is a private company and its shares of common stock and preferred stock are not publicly traded.
MARKET PRICE AND DIVIDEND INFORMATION. Ohr common stock trades on Nasdaq under the symbol “OHRP.” The following table details the high and low closing prices for the Ohr common stock as reported by Nasdaq for the periods indicated. On January 23, 2019, Xxx filed with the Secretary of State of the State of Delaware a Certificate of Amendment to its Certificate of Incorporation to effect a one-for-twenty reverse stock split. The shares of Ohr common stock began trading on a split adjusted basis when the market opened on February 4, 2019. The share prices below are shown on a post-split basis. Price Range (1) Fiscal Year 2017 High Low First Quarter $ 75.00 $ 30.00 Second Quarter 33.00 15.60 Third Quarter 18.40 12.00 Fourth Quarter 15.80 11.40 Fiscal Year 2018 First Quarter $ 38.40 $ 11.80 Second Quarter 40.80 4.40 Third Quarter 6.60 3.80 Fourth Quarter 4.80 3.00 Fiscal Year 2019 First Quarter $ 6.20 $ 1.80 Second Quarter 3.60 1.92 Third Quarter (through June 5, 2019) 3.10 2.21
MARKET PRICE AND DIVIDEND INFORMATION. STPK STPK’s units, Class A Common Stock and public warrants are currently listed on the NYSE under the symbols “STPK.U,” “STPK,” and “STPK WS,” respectively. The closing price of the units, the Class A Common Stock and the public warrants on December 3, 2020, the last trading day before announcement of the execution of the merger agreement, was $10.50, $10.06 and $1.33, respectively. As of March 4, 2021, the record date for the STPK Special Meeting, the most recent closing price for each unit, Class A Common Stock and public warrant was $30.07, $26.41 and $13.90, respectively. Holders of the units, Class A Common Stock and public warrants should obtain current market quotations for their securities. The market price of STPK’s securities could vary at any time before the merger.
MARKET PRICE AND DIVIDEND INFORMATION. The closing price of Aduro common stock on June 1, 2020, the last trading day prior to the public announcement of the merger, was $3.37 per share and the closing price of Aduro common stock on August 25, 2020 was $3.02 per share, in each case as reported on Nasdaq. Because the market price of Aduro common stock is subject to fluctuation, the market value of the shares of Aduro common stock that Chinook stockholders will be entitled to receive in the merger may increase or decrease. Chinook is a private company and its shares of common stock and preferred stock are not publicly traded. Dividends Aduro has never declared or paid cash dividends on its capital stock and does not anticipate paying any cash dividends in the foreseeable future. Chinook has never paid or declared any cash dividends on its capital stock. Chinook intends to retain all available funds and any future earnings for use in the operation of its business and does not anticipate paying any cash dividends on its capital stock in the foreseeable future. Notwithstanding the foregoing, any determination to pay cash dividends subsequent to the merger will be at the discretion of the combined company’s board of directors and will depend upon a number of factors, including the combined company’s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors the combined company’s board of directors deems relevant.
MARKET PRICE AND DIVIDEND INFORMATION. The closing price of Millendo common stock on March 26, 2021, the last trading day prior to the public announcement of the merger, was $2.18 per share and the closing price of Millendo common stock on May 10, 2021 was $1.08 per share, in each case as reported on The Nasdaq Capital Market. Because the market price of Millendo common stock is subject to fluctuation, the market value of the shares of Millendo common stock that Tempest stockholders will be entitled to receive in the merger may increase or decrease. Tempest is a private company and its shares of common stock and preferred stock are not publicly traded.
MARKET PRICE AND DIVIDEND INFORMATION. Tocagen Common Stock is currently listed on The Nasdaq Global Select Market under the symbol “TOCA.” Forte is a private company and its common stock and preferred stock are not publicly traded. Tocagen Common Stock The closing price of Tocagen Common Stock on February 18, 2020, the full trading day immediately prior to the public announcement of the Merger on February 19, 2020, as reported on The Nasdaq Global Select Market, was $0.5440 per share. The closing price of Tocagen Common Stock on May 12, 2020, as reported on The Nasdaq Global Select Market, was $1.15 per share. Because the market price of Tocagen Common Stock is subject to fluctuation, the market value of the shares of Tocagen Common Stock that Forte stockholders will be entitled to receive in the Merger may increase or decrease. Assuming successful application for initial listing with Nasdaq, following the consummation of the Merger, Tocagen anticipates that the Tocagen Common Stock will continue to be listed on The Nasdaq Capital Market and will trade under Tocagen’s new name “Forte Biosciences, Inc.” and new trading symbol “FBRX” on The Nasdaq Capital Market As of April 20, 2020, the record date for the Tocagen special meeting, there were approximately 311 holders of record of the Tocagen Common Stock.
MARKET PRICE AND DIVIDEND INFORMATION. Trine Trine’s Class A common stock, units and public warrants and are traded on the NYSE under the symbols TRNE, TRNE.U and XXXX.XX, respectively. The closing price of the Class A common stock, units and public warrants on August 25, 2020, the last trading day before announcement of the execution of the Merger Agreement, was $10.14, $11.22 and $1.07, respectively. As of October 30, 2020, the Trine Record Date, the most recent closing price for each Class A common stock, unit and public warrant was $10.20, $11.17 and $1.70, respectively. Holders of the Class A common stock, units and public warrants should obtain current market quotations for their securities. The market price of Trine’s securities could vary at any time before the Business Combination.
